Author: Dino Mustafić

May 23, 2017 Off

Novo Nordisk submits application in the US for label addition for its diabetes drug

By Dino Mustafić

Novo Nordisk has submitted a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.

Anavex presents new data for certain neuro-diseases tratment
May 22, 2017 Off

Anavex presents new data for certain neuro-diseases tratment

By Dino Mustafić

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, has announced new preclinical data for ANAVEX 2-73 in the neurodevelopmental disorders Angelman syndrome, Fragile X syndrome and Rett syndrome.

100 Healthy Years – Are Kids Prepared?
May 19, 2017 Off

100 Healthy Years – Are Kids Prepared?

By Dino Mustafić

Merck, one of the worlds most renown science and technology companies, summoned experts from worlds organizations such as UN, UNICEF, UNAIDS, World Obesity Federation and McKinsey at the the company’s headquarters in Darmstadt, Germany, to discuss questions about the most urgent threats to our children’s long-term health, or what can be done both inside and outside the classroom? And how do schools, parents and communities share responsibility?

Arix bags $65 million in a B series investment round
May 19, 2017 Off

Arix bags $65 million in a B series investment round

By Dino Mustafić

Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. “Arix is delighted to have led this $65m funding round comprising many of the biotech sector’s leading specialist investors,” said…

argenx raises approximately $100 million gross proceeds
May 18, 2017 Off

argenx raises approximately $100 million gross proceeds

By Dino Mustafić

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its initial public offering in the United States with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS.